The randomized patients with acute heart failure will be stratified based on the presence or
absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the
first 30 minutes and 1 mg/h thereafter or matching placebo in a 1: 1 manner. The duration of
the treatment is 24 hours up to 72 hours. The duration of the follow-up period is 30 days
after treatment initiation for death, re-hospitalizations and SAEs followed by a follow-up
period of 5 months for vital status.
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Concord Repatriation Hospital, Concord Nsw, Australia
Queen Elizabeth Hospital, Woodville Sa, Australia
Faculty Hospital St. Anna, Brno, Czech Republic
Krajska Nemocnice Liberec, Liberec Husova 10, Czech Republic
Klinika Kardiologie IKEM, Prague, Czech Republic
University Hospital Vinohrady (FNKV), Prague, Czech Republic
Masaryk Hospital, Usti Nad Labem, Czech Republic
Universitatsklinikum der Humboldt-Universitat Berlin, Campus Charite Mitte, Med. Klinik und Poliklinik, Kardiologie, Berlin, Germany
Universitat Greifswald, Klinik fur Innere Medizin B, Greifswald, Germany
Asklepios Klinik Langen, Abteilung fur Innere Medizin, Langen, Germany
Universitatsklinikum Schleswig Holstein, Medizinische Klinik II, Kardiologie, Lubeck, Germany
Klinik u. Poliklinik F. Inn. Med. II, Univ. Klinik Regensburg, Regensburg, Germany
Jahn Ferenc, Delpesti Korhaz, Budapest, Hungary
Polyclinic of the Hospitaler Brothers of St. John of God, Budapest, Hungary
University of Debrecen, Debrecen, Hungary
2nd Department of Medicine & Cardiology Centre, Szeged, Hungary
Cattedra di Cardiologia, c/o Spedali Civili, Brescia, Italy
Istituto Clinico Humanitas, U.O. Cardiologia Clin. E Insuff. Cardiaca, Rozzano (mi), Italy
Sentralsykehuset i More og Romsdal, Dept. of Cardiology, Alesund, Norway
Aker University Hospital, Div. Cardiology, Oslo, Norway
Central Hospital in Rogaland, Cardiology Division, Stavanger, Norway
University Department of Medicine, City Hospital, Birmingham, United Kingdom
Cardiology Department, Bridlington & District Hospital, Bridlington, United Kingdom
University of Glasgow West, Glasgow, United Kingdom
Dept. of Medicine & Therapeutics, University of Leicester, Leicester, United Kingdom
Oracle Research, Huntsville, Alabama, United States
USC Medical Center, Los Angeles, California, United States
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
University of Miami-Jackson Memorial Hospital, Miami, Florida, United States
University Hospital, Augusta, Georgia, United States
University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
Medical Research Institute, Slidell, Louisiana, United States
Baystate Medical Center-Cardiology Section, Springfield, Massachusetts, United States
Elmhurst Hospital Center, Elmhurst, New York, United States
Columbia Presbyterian Medical Center-Heart Failure Center, New York, New York, United States
New York University School of Medicine, New York, New York, United States
University of North Carolina, Chapel Hill, North Carolina, United States
Duke University Medical Center, Durham, North Carolina, United States
LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina, United States
Baylor College of Medicine - Texas Medical Center, Houston, Texas, United States
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Alfred Hospital, Monash University, Central and Eastern School, Prahran, Victoria, Australia